Chronic Lymphocytic Leukemia

Bita Fakhri, MD, MPH, discusses considerations in selecting the optimal treatment in chronic lymphocytic leukemia.

Armed with the knowledge that inhibition of the Bruton tyrosine kinase is an effective approach in B-cell malignancies, investigators will explore the efficacy of the second-generation BTK inhibitor, zanubrutinib, in 2 leukemia and lymphoma subtypes.

Jennifer A. Woyach, MD, discusses the evolving treatment paradigm and sequencing challenges in chronic lymphocytic leukemia.

Lori A. Leslie, MD, discusses a retrospective analysis of real-world patients with chronic lymphocytic leukemia who were treated with acalabrutinib (Calquence).

Jennifer Woyach, MD, discusses the results of the ELEVATE-TN trial in patients with treatment-naïve chronic lymphocytic leukemia.

Jennifer Woyach, MD, discusses frontline treatment options for patients with chronic lymphocytic leukemia.

Bita Fakhri, MD, MPH, discusses the trials that led to ibrutinib-containing regimens becoming the standard of care for chronic lymphocytic leukemia over traditional chemotherapy options.

Matthew S. Davids, MD, MMSc, associate director, Center for Lymphocytic Leukemia, physician, Dana-Farber Cancer Institute, and assistant professor of medicine, Harvard Medical School, discusses the potential cost effectiveness of a 12-month fixed duration of venetoclax (Venclexta) in combination with obinutuzumab (Gazyva) in first-line chronic lymphocytic leukemia (CLL).

Anthony R. Mato, MD, MSCE, discusses the phase III CLL14 trial in patients with previously untreated chronic lymphocytic leukemia.

Anthony R. Mato, MD, MSCE, discusses recent treatment advances that have been made in the frontline and relapsed/refractory settings of chronic lymphocytic leukemia.